Okay, we're going to get started. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies. Thank you for joining us today. I have the pleasure to have the Xenon team with me. To my direct left is Ian Mortimer, CEO, and to his left, Tucker Kelly, CFO. Welcome, both of you.
Thank you, Andrew.
Thank you.
Maybe to get started, remind us the latest and greatest. You've shown some unprecedented phase III epilepsy data earlier this year, but it'd be nice to give the audience an overview about Xenon and the milestones over the next 6-12 months would be helpful.
Yeah, perfect. Happy to jump in, give a bit of an overview, and then I know we'll do Q&A throughout. First, thanks very much for hosting us. Always a great week in London and busy schedule. This has really been an important year for Xenon. This is the very first time we've unblinded a phase III clinical trial, our very first new drug application, and getting ready to be a commercial organization. If we just take a step back, we really think about the business in three primary components.
Our lead program, azetukalner, that's being developed in multiple forms of epilepsy. We're expanding azetukalner into a broad psychiatry program. Then we have a really interesting early-stage portfolio that has just finished phase I. These are two assets on two different targets that are going to be developed in pain indications, and we'll go into phase II next year. So I think the business has been really productive over the last 12 months, and lots coming as we look forward over the next 6- 12 months.
If I start with azetukalner in epilepsy, we had the phase III data in March of this year. That was our X-TOLE2 study, which exceeded all of our expectations, and I think the expectations of the street, where on a placebo-adjusted basis, we're seeing the best efficacy ever seen in a focal onset seizure study and obviously, that was a key component of filing our new drug application in September of this year. We expect that application will be accepted here shortly with a PDUFA date next fall.
So we're doing a lot to get ready for commercialization for our first product in a launch in epilepsy. And then as we move into psychiatry, we're going to have our first phase III MDD readout in major depressive disorder. Study's called X-NOVA2. It's the same molecule, azetukalner. And I know we'll go through some detailed questions on the depression program as we move through the next half hour. And then as I mentioned, the pain portfolio is really exciting at Xenon. We've got two molecules, a drug called XEN1701 on a target called NAV1.7.
I think this has been an incredibly challenging but exciting target for many, many years, and I think we have really unique chemistries and a profile in phase I that's never been seen before, and we're excited to move that into a phase II study next year. Then we've got a Kv7 drug called XEN1120, which will also move into a phase II proof of concept study.
Great. Thank you. Maybe a couple of housekeeping questions to start. Typically, at AES, you have a presence there. Secondly, typically, J.P. Morgan January, you give some business updates. Anything meaningful we can expect?
Sure. I can start on AES, and then Tucker can add just on the business over the next 12 months or so and some guidance at J.P. Morgan. So AES is the American Epilepsy Society meeting, takes place in early December every year, the largest medical congress dedicated to epilepsy. A huge opportunity for us to continue to build Xenon as a trusted partner in the epilepsy community, but also raise the profile of azetukalner. We will have a huge team there. We will have more than 50 Xenon employees.
We have had MSLs in the field for a couple of years, and we are now starting to build the leadership in our commercial organization. So it is a really great opportunity for us to connect with prescribers and patient advocacy groups and really raise the profile of Xenon and azetukalner. In terms of presentations, there will be a few things we are going to focus on this year. One, we will have our five-year or 60-month data from our phase II X-TOLE study. So the patients that finished the double-blind period can go into open-label extension. That started as a one-year OLE. We have extended it first to two, three, five, and now it is a seven-year open label.
We have patients that are doing incredibly well when they are staying on drug for long periods of time. The data we had a year ago, about two in five patients, close to 40%, had 12 months of seizure freedom if they were on the drug for four years. So really remarkable long-term seizure freedom data. We will mature those data one more year, so it will be the 60-month data. So I think that will be a critical update for the epilepsy community. The other thing that we will do is we are going to show some additional analyses from our X-TOLE2 data.
If you remember, Andrew, what we have seen in the past when we looked at the X-TOLE data is we started looking at different subgroups within the dataset and s o we are going to look at those subgroups again in X-TOLE2, and we are going to provide the data on a combined basis. So if you think about a new drug application, two key sections of an NDA is your integrated summaries of efficacy and safety. So we will have a poster on the ISE and ISS where we looked at the entire profile. You can think about this more as what the label will look like.
Sure.
So Looking overall at ISE and ISS data at AES. So those will be two new clinical updates, and then we'll have a lot of presence on a number of the other programs. We also do a corporate reception and a scientific exhibit to raise the profile of Xenon.
Mm-hmm. Okay.
As Ian outlined before, across the three pillars of the business, it's going to be a busy 2027. So certainly we'd expect FDA approval. We filed in September of this year. We'd expect the standard review, so we'd get FDA approval in September of 2027 and w e expect to have DEA scheduling. Most ASMs are scheduled, so that builds an additional three months, so launch will really be beginning of 2028, but c ertainly the commercial prep work we'll be doing, finalizing label negotiations, getting ready for that first FDA approval on azetukalner in epilepsy will be big. We'll continue enrollment in our X-TOLE3 study in Japan, which we've discussed earlier this year.
We got alignment with PMDA to have some subjects taken out of the global program and used for Japanese potential approval and t hen we announced at Q3 we're going to have X-FIRST. It'd be a new study that we're starting. That'll be a phase III-b/IV. This study is designed to look at earlier line epilepsy patients, so patients that have been on one or two monotherapy approaches, and this would be the first add-on, hence X-FIRST and t hat we've said we'll start in the first half of 2027. That'll be a really helpful study, we think, because we'll talk about the profile of azetukalner and how we think it'll be used commercially.
Being able to have experience with general neurologists more than epileptologists in earlier line patients rather than the more refractory ones we saw will be really, really useful. So a lot of good updates across the epilepsy program as well and then o n psychiatry, obviously, we will have the readout we will touch on here in December, but assuming a positive outcome, we will have additional updates based on our interactions with the agency and restarting enrollment there.
And then on the pain side that Ian touched on earlier, we finished off two phase I's. We have guided to having two proof of concepts in acute pain starting. That will be in the first half of next year and then o n the early-stage pipeline, we have a really active research engine. So, if we are fortunate enough to have some of our earlier programs kind of make it through IND and tox, that may be something else we will have for 2027. So, should be a very active period for us.
For sure. And sticking with epilepsy, as you mentioned, Ian, you submitted the NDA, I think in my notes, September 17th. It is 60 days already. Things are okay? You still expect to be accepted for the NDA?
Yeah, and the FDA gets back to sponsors between day 60 and day 74. So when we have a PDUFA date from FDA, then we will disclose that publicly.
Great. As for the label, as we think about the label, anything unique that you think could be included in the label? I think at one point maybe we were discussing rapid efficacy, but maybe, I do not know if that is an aggressive language in the label claim. Otherwise, I think also when I think about the predecessor drug, there is POTIGA, which had a black box for vision pigmentation, I believe, and you do not expect that, to be clear?
Yeah, I think it's a little premature to be talking about label.
Sure.
As we file a new drug application, we submit a draft label from the sponsor's perspective, and obviously that would be negotiated through the review period. But if you actually look at all of the drugs to treat focal onset seizures and you look at the labels, you have pretty consistency across the different labels and so I think there's real precedent on what's included in the label from both an efficacy and a safety point of view. And then obviously, all of these data that we've been able to generate that I talked about even at AES is an opportunity to continue to communicate that from a medical communications perspective in addition to what will be the labeled claims.
Great. And then, maybe quickly is just like, the most recent branded drug was XCOPRI, on track to do $1 billion in peak sales. So I just want to make sure you guys are still confident you can do more than $1 billion at peak.
Yeah, maybe I'll start just on the profile and t hen Tucker can kind of I think this is a good opportunity for us to transition a little bit into how we're preparing for the commercial opportunity of azetukalner. I think azetukalner is a really important medicine in epilepsy. It's really been rare that we've seen this type of innovation and the type of attributes that a drug like azetukalner has. This will be the first time in many, many years where we've seen a novel mechanism with the type of efficacy profile we have.
I think the side effect and tolerability profile is completely appropriate for an antiseizure medicine, and we feel very comfortable, b ut also, the drug doesn't need to be titrated. We don't have risk of drug-drug interactions with other ASMs. So we really have a profile that really hasn't been seen in epilepsy that we think will do well, not only for the specialists, which are the epileptologists that see patients at level three and level four centers, but also for the general neurologists. And there's a lot of general neurologists, almost 20,000 in the U.S., that see lots of epilepsy patients that historically haven't used all of the branded medicines because they've been more challenging to prescribe, including XCOPRI a nd so, I do think azetukalner has a very different overall profile that will do well commercially.
Yeah, and just to add onto that, again, I think when we think about where this drug can be used well, it is in that broader general neurology call point. We also think pricing in epilepsy has not sort of caught up to maybe where drug pricing is today. So, we haven't guided specifically where we'll land on price, but we have said it's going to be something north of where cenobamate or XCOPRI is today. They're about $15,400 annualized gross. And where BRIVIACT, which went off patent earlier this year, they were about $18,000. So we think certainly on price we'll do it, but as Ian said, I think the real opportunity for azetukalner is kind of getting broader and deeper penetration given all the attributes that he outlined before.
I see. And then to solidify your real-world positioning, you mentioned earlier, Tucker, you're starting the X-FIRST study. I believe that's like a third-line patient population And s o, based on my doctor discussions, they're telling me we generally see stronger efficacy in earlier lines of therapy. I think you showed that in the original phase II. We have yet to see that in this phase III. So the question is, ultimately for the study, could the seizure freedom, for instance, be pretty powerful of a data point, like really strong seizure freedom than compared to what you saw in the phase IIIs so far.
Yeah. So this is going to be an open-label kind of observational study that we'll run. So it won't be powered in the same way as a kind of randomized placebo-controlled study, but we think it's going to give us really good experience with having the drug in earlier line patients. As you said, we've had data before from the phase II-B, showing that, not surprisingly, in earlier line patients that are having fewer seizures, they haven't had exposure to as many ASMs, that they can have a higher seizure reduction, longer duration of time without seizures.
So, we think there's really strong rationale for why it will be a really effective agent earlier on. And the other thing to note is, again, we got a novel mechanism. There's no other potassium channel modulators out there today, and there's a lot of drugs approved for epilepsy, but they really cluster in just a couple of broad mechanisms. So we do think after somebody's seen an SV2A or a sodium channel blocker, that first add-on time is a great point at which a physician could think about adding in potassium modulation as a way to try and manage seizures, but also to provide a different way of trying to do that rather than maybe cycling through another sodium channel blocker or going to a different SV2A or looking at some of the other agents that are used.
So we think it's going to provide really good evidence for those earlier line patients. It may not generate the sort of higher level of evidence that you'd look at in a randomized control trial. It wouldn't be a label-enabling, but we think it'll be something that could be communicated with scientific communication and certainly provide good experience in earlier line patients.
Okay. Very clear. Then maybe shifting gears to azetukalner for MDD, because there's a big phase III readout coming in December. Earlier this year, I think in September, you decided to pause enrollment for the other depression trials. This one is still on track, to be clear, for December. You pulled that forward. sO Can you just remind us what exactly prompted that to happen? What exactly did you see on the AE front?
Yeah, I think it's helpful here to maybe take a few steps back and just walk through a little bit of the history. We believe that potassium channel modulation in Kv7.2, generally, but specifically azetukalner, has an antidepressant effect. We've seen four different studies, two with ezogabine and two with azetukalner, where the active drug outperforms placebo, and higher doses of the drug outperform lower doses of the drug. I think we have enough information that we feel comfortable that this has an antidepressant effect.
Based on that, we ran a smaller phase II proof-of-concept study called the X-NOVA study, and when we unblinded that, we did show clear separation between active and placebo, b ut that study had a really benign safety profile in the active arms. Actually, it had a safety profile that was more benign than we expected going into unblinding those data. As we've got into a larger phase III program in psychiatry, so today we're running three phase III clinical trials, two in major depressive disorder, X-NOVA2 and X-NOVA3, and one in bipolar depression that we call the X-CEED study.
As we got more into that study, on a blinded basis, the adverse event profile looks more like the type of adverse events that we see in epilepsy. Obviously, we have a lot more experience in epilepsy, where we've completed two large randomized placebo-controlled studies. We have lots of open-label data in patients on the drug for many, many years and s ome of those adverse events that we didn't see in the phase II depression study, we're starting to see in the phase III depression study. So b ased on that information and in consultation with our DSMB, we made a decision on a couple of things in September. One, we made a decision to pause new enrollment.
So patients that were continuing on therapy, either in a double-blind or open-label, continued, and we made a decision to complete X-NOVA2 and unblind those data. Those will be the data that'll be available next month. So that study completes with about— we've now completed all of the dosing. We're just doing the safety follow-up and data cleaning to be in a position to unblind data in December. That'll have about 360 subjects randomized, which gives us 90% power for a 2.5-point separation on the primary endpoint, which is HAMD-17 at week six.
So we feel really good about that. Once we unblind those data, then we'll now have the unblinded data on benefit-risk of azetukalner in psychiatry in a large phase III study, which will then give us the information to make a determination on whether we continue to do development in psychiatry or whether we really focus azetukalner only in epilepsy.
I see. To be clear, the specific blinded AE rates that you saw, I think it was like low instances of psychosis, I think in my notes, aphasia, ataxia, confusion. To be clear, it's not like those rates exceeded what you've already seen in epilepsy. I want to emphasize that.
Yeah, I think, again, we know a lot about the safety profile of this medicine. One of the things that we communicated in September is on a blinded basis, we are not seeing any new safety or adverse events that we have not seen previously. It is blinded data, but we do not believe they are going to be at a higher rate or an increase in severity. We also know that if any patient has an adverse event and comes off drug, any adverse event is reversible with no long-term sequelae.
So again, I think we have a really good understanding of the profile. When we think about the safety profile overall, we have more. This is a very potent mechanism of dampening hyperexcitability in the brain. You see more common adverse events that are dose-dependent, things like dizziness and somnolence. Then we see events that are under 10% that are dose-dependent, things like some confusion or word finding. So we did see some of those adverse events in epilepsy, and we are starting to see them in psychiatry.
And then we have really rare events that happen that are SAEs or the odd event of psychosis and a gain, as we work through those events, as patients come off drug, events are reversible with no long-term sequelae. So again, we have a great amount of information and detail and comfort around the safety profile. I do not think it is going to be different, and it absolutely has no impact on the work that we are doing in epilepsy
Mm-hmm. And if the December readout does read out positively, is it still counted as a pivotal study even though you truncated a little bit?
Yeah, we believe so. Since the update in September, we have had the opportunity to interact with FDA, and we did a couple of things. One, we let FDA know what we were doing in the broad phase III program in psychiatry, but we also let them know what we were doing with X-NOVA2, which was that we were going to complete enrollment at 360 subjects. We had the power calculations that we had, so we were going to have that adjustment in sample size and s o they are well aware of what we are doing.
I mean, we can never say whether a program is pivotal registration. Those are always review issues. But at the end of the day, we feel very comfortable with the decision, and that has been communicated with the agency, and the agency has not pushed back on that. As Tucker mentioned earlier, one of the important steps after unblinding X-NOVA2, when we have that unblinded data, we really understand benefit risk in MDD, then an opportunity to go back, engage with the FDA, have a conversation on the path forward.
Yeah. And knowing what you know right now, totally understood if you don't want to say much at this juncture, but let's just say the AE rates are, we know the AE rates are in line with epilepsy, but has your view on the peak sales potential in depression, for instance, changed based on this update?
Yeah. So we've never kind of provided peak sales estimates on azetukalner in depression or in epilepsy, frankly. But look, we went into the depression studies and neuropsychiatry with a perspective that this could have an effect on depression, on mood, and that it would bring a different safety and tolerability profile. So something novel in terms of mechanism, but also in terms of what AEs people see typically, whether on SSRIs or SNRIs. So, I think what we decided to do in September was really try and operationalize something that we thought could help ameliorate the potential adverse event profile a little bit, improve the tolerability, because we think that's an important factor in prescribing in MDD.
What we see in our research is that oftentimes, you need efficacy to kind of get an approval, get across that finish line, but that the prescribing decision is often based on what other mechanisms have they tried before, or what adverse event profile are they interested in trying to balance off against potential efficacy. So, we think we still have a compelling profile and differentiated, but we do think it would be important to try and make sure that we optimize that as much as we could to give the drug the best chance of success commercially.
Okay. Thank you. Good luck on that next month. And so maybe shifting gears to the pain program. Like you said, you are starting phase II acute pain studies in 2027. I would imagine that is first half, but the question is, could we get the acute pain data second half of 2027, since these are pretty short studies for both programs?
Yeah, I think unlikely. So I think we are incredibly happy with the phase I profile, where I think with both mechanisms, whether it be NAV1.7 or Kv7, I believe we have a profile where we can truly test whether these mechanisms have an analgesic effect. So the first study will be these proof of concept studies. Often they are a bunionectomy study or an abdominoplasty study. Those will start in the first half of next year. Yes, you are right, those studies can enroll quite quickly. It is unlikely that you have data in under 12 months, but they can enroll quite quickly but w e also want to design those studies of sufficient size that we can start to answer some important questions.
Obviously, we want to see the analgesic effect, but in a phase II study, we want to study multiple doses.
We also want to think about an active comparator, so we can put those data into context with other molecules and other mechanisms that have been tried recently in acute pain. I think NAV1.7 is one of the most fascinating targets. The genetics are incredible on this target. It has been an incredibly difficult target to drug, and I think we have a chemistry and a profile that is never been seen before, which is truly be able to run the first time the human experiment. Can we mimic the human genetics where these patients feel no pain?
Yeah. And I think in the phase I studies that you have conducted, the receptor occupancy is very, very high.
Yeah.
Is there any data to correlate very high receptor occupancy to the actual pain reduction ultimately in either acute or chronic pain?
So we're really being driven and taught by the genetics. So there are patients that have somewhere between a 75% and 85% loss of function of the channel, that have this phenotype where they feel no pain. It's called CIP, a congenital indifference or insensitivity to pain. We know based on our receptor occupancies, both centrally, as in both in the peripheral nervous system as well as centrally, and we've done CSF in the phase I study, that we can get well above that, and at our higher doses, we're getting above 90% receptor occupancy.
Okay. So the Kv7 NAV1.7 going to acute pain, can you remind me different types of acute pain? Are there going to be multiple phase IIs per program or just one phase II?
Yeah. So we'll start in each case with a kind of, I think, well-validated model. In the acute pain, typically there's two that folks would run. One's an abdominoplasty, the other is a bunionectomy, so w e'll do one in abdominoplasty, the other will be in bunionectomy. And then again, if you're moving forward with a label, typically what you'll do is you'll kind of flip and do the other acute pain model, followed by kind of more open label work and a broader range of surgeries or procedures. So first port for us is to get into that POC, and we'll do one bunionectomy and one abdominoplasty between the two programs.
Okay. And then from there, then you can feel confident in going to chronic pain. How many chronic pain types of studies would you be doing?
Yeah, good question. We don't have any answer for you today. Look, chronic pain is ultimately where the big market is. Vertex did a lot of work on the acute side to build a market there, but I think the Holy Grail is to get a chronic pain drug approved that's a non-opioid-based approach to analgesia. Let us get through the POCs in acute. I think that'll really validate the mechanism that, as Ian said, we and others have worked on for decades now. And if it works there, then we think there's strong evidence that it could work in chronic pain, and there's a variety of different ways you can go for in terms of getting a chronic pain label.
Okay. Very good. I think that's all the time we have, and thank you for sharing all the progress. Best of luck, and thanks everyone for listening.
Thank you.
Thanks, Andrew.